|
C1ORF25 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.23470053362496E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.48659995424794E-09 |
| Normal-vs-Stage2 |
1.13689999969857E-07 |
| Normal-vs-Stage3 |
5.82750514510622E-11 |
| Normal-vs-Stage4 |
1.92360000150771E-08 |
| Stage1-vs-Stage2 |
9.034800E-01 |
| Stage1-vs-Stage3 |
3.858400E-01 |
| Stage1-vs-Stage4 |
4.126200E-01 |
| Stage2-vs-Stage3 |
5.148000E-01 |
| Stage2-vs-Stage4 |
4.869800E-01 |
| Stage3-vs-Stage4 |
9.036400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.86309984001798E-10 |
| Normal-vs-AfricanAmerican |
5.553000E-04 |
| Normal-vs-Asian |
4.80660000690136E-09 |
| Caucasian-vs-AfricanAmerican |
2.113000E-01 |
| Caucasian-vs-Asian |
8.965800E-01 |
| AfricanAmerican-vs-Asian |
1.907170E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.38850092218968E-11 |
| Normal-vs-Female |
5.61509949648098E-10 |
| Male-vs-Female |
7.360600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.5758000177234E-09 |
| Normal-vs-Age(41-60Yrs) |
1.02162722726007E-12 |
| Normal-vs-Age(61-80Yrs) |
5.21049980939381E-10 |
| Normal-vs-Age(81-100Yrs) |
3.780500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.719200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.975200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.379200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.270400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.415000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.674800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.000800E-03 |
| Classical-VS-Follicular |
1.474010E-01 |
| Classical-VS-Other |
5.125800E-01 |
| Classical-VS-Normal |
2.77060000497542E-08 |
| Tall-VS-Follicular |
1.557590E-01 |
| Tall-VS-Other |
5.791600E-01 |
| Tall-VS-Normal |
1.36299971309484E-10 |
| Follicular-VS-Other |
8.540200E-01 |
| Follicular-VS-Normal |
2.73029998609786E-09 |
| Other-VS-Normal |
4.998200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.84469994835013E-10 |
| Normal-vs-N1 |
6.89849954937927E-10 |
| N0-vs-N1 |
4.728000E-01 |
|
|
